MassBank MassBank Search Contents Download

MassBank Record: PR300917

(+)-Chelidonine; LC-ESI-QTOF; MS2

Mass Spectrum
Chemical Structure
Generated by the Chemistry Development Kit (http://github.com/cdk)

ACCESSION: PR300917
RECORD_TITLE: (+)-Chelidonine; LC-ESI-QTOF; MS2
DATE: 2019.03.28
AUTHORS: Tetsuya Mori, Center for Sustainable Resource Science, RIKEN
LICENSE: CC BY-SA NC
PUBLICATION: Tsugawa H., Nakabayashi R., Mori T., Yamada Y., Takahashi M., Rai A., Sugiyama R., Yamamoto H., Nakaya T., Yamazaki M., Kooke R., Bac-Molenaar JA., Oztolan-Erol N., Keurentjes JJB., Arita M., Saito K. (2019) "A cheminformatics approach to characterize metabolomes in stable-isotope-labeled organisms" Nature Methods 16(4):295-298. [doi:10.1038/s41592-019-0358-2]
COMMENT: registered in RIKEN PlaSMA

CH$NAME: Chelidonin
CH$NAME: (+)-Chelidonine
CH$NAME: [1,3]Benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridin-6-ol, 5b,6,7,12b,13,14-hexahydro-13-methyl-, (5bR,6S,12bS)-
CH$COMPOUND_CLASS: Hexahydrobenzophenanthridine alkaloids
CH$FORMULA: C20H19NO5
CH$EXACT_MASS: 353.126323
CH$SMILES: CN1CC2=C(C=CC3=C2OCO3)[C@@H]4[C@H]1C5=CC6=C(C=C5C[C@@H]4O)OCO6
CH$IUPAC: InChI=1S/C20H19NO5/c1-21-7-13-11(2-3-15-20(13)26-9-23-15)18-14(22)4-10-5-16-17(25-8-24-16)6-12(10)19(18)21/h2-3,5-6,14,18-19,22H,4,7-9H2,1H3/t14-,18-,19+/m0/s1
CH$LINK: CAS 476-32-4
CH$LINK: CHEMSPIDER 171216
CH$LINK: COMPTOX DTXSID10878474
CH$LINK: INCHIKEY GHKISGDRQRSCII-ZOCIIQOWSA-N
CH$LINK: PUBCHEM CID:197810

AC$INSTRUMENT: LC, Waters Acquity UPLC System; MS, Waters Xevo G2 Q-Tof
AC$INSTRUMENT_TYPE: LC-ESI-QTOF
AC$MASS_SPECTROMETRY: MS_TYPE MS2
AC$MASS_SPECTROMETRY: ION_MODE POSITIVE
AC$MASS_SPECTROMETRY: COLLISION_ENERGY 6V
AC$MASS_SPECTROMETRY: DESOLVATION_GAS_FLOW 800/h
AC$MASS_SPECTROMETRY: DESOLVATION_TEMPERATURE 450 C
AC$MASS_SPECTROMETRY: IONIZATION ESI
AC$CHROMATOGRAPHY: CAPILLARY_VOLTAGE +3.00 kV
AC$CHROMATOGRAPHY: COLUMN_NAME Acquity bridged ethyl hybrid C18 (1.7 um, 2.1 mm * 100 mm, Waters)
AC$CHROMATOGRAPHY: COLUMN_TEMPERATURE 40 C
AC$CHROMATOGRAPHY: FLOW_GRADIENT A/B = (99.5%/0.5% at 0 min, 99.5%/0.5% at 0.1 min, 20%/80% at 10 min, 0.5%/99.5% at 10.1 min, 0.5%/99.5% at 12.0 min, 99.5%/0.5% at 12.1 min, 99.5%/0.5% at 15.0 min)
AC$CHROMATOGRAPHY: FLOW_RATE 0.3 ml/min at 0 min, 0.3 ml/min at 10 min, 0.4 ml/min at 10.1 min, 0.4 ml/min at 14.4 min, 0.3 ml/min at 14.5 min
AC$CHROMATOGRAPHY: RETENTION_TIME 4.533533
AC$CHROMATOGRAPHY: SOLVENT A water including 0.1% formic acid
AC$CHROMATOGRAPHY: SOLVENT B acetonitrile including 0.1% formic acid

MS$FOCUSED_ION: PRECURSOR_TYPE [M+H]+
MS$FOCUSED_ION: PRECURSOR_M/Z 354.1335992

PK$SPLASH: splash10-004j-0190000000-87c0159801293da6b985
PK$NUM_PEAK: 64
PK$PEAK: m/z int. rel.int.
  135.04376 77.0 77
  135.04999 18.0 18
  136.05013 11.0 11
  143.0495 12.0 12
  144.05658 7.0 7
  149.05463 5.0 5
  159.04793 14.0 14
  161.05505 23.0 23
  161.06342 13.0 13
  163.04004 78.0 78
  173.06064 23.0 23
  176.06688 11.0 11
  176.07321 10.0 10
  187.03543 7.0 7
  188.06839 33.0 33
  188.07828 15.0 15
  189.07274 97.0 97
  190.07504 10.0 10
  207.05995 6.0 6
  207.08165 15.0 15
  217.06053 48.0 48
  217.07033 43.0 43
  218.05963 10.0 10
  218.06985 15.0 15
  219.07918 10.0 10
  235.07059 10.0 10
  235.07962 26.0 26
  236.07765 6.0 6
  237.08969 41.0 41
  238.09924 11.0 11
  245.0571 26.0 26
  245.06873 15.0 15
  246.05696 8.0 8
  246.06941 6.0 6
  247.0761 563.0 562
  248.08057 132.0 132
  249.07697 9.0 9
  249.09496 15.0 15
  263.07532 5.0 5
  265.07028 15.0 15
  265.07819 19.0 19
  265.08981 41.0 41
  266.08524 8.0 8
  266.09683 7.0 7
  275.01413 7.0 7
  275.07144 1000.0 999
  276.04416 8.0 8
  276.07504 237.0 237
  276.10846 6.0 6
  277.07028 12.0 12
  277.08191 20.0 20
  293.08136 28.0 28
  294.08182 6.0 6
  295.08273 6.0 6
  295.09808 29.0 29
  305.07303 15.0 15
  305.08939 20.0 20
  306.08612 5.0 5
  323.08636 20.0 20
  323.09915 16.0 16
  323.11221 12.0 12
  336.12357 18.0 18
  336.13672 6.0 6
  354.13358 8.0 8
//

Imprint Feedback
system version 2.1.8
Copyright © 2006 MassBank Project; 2011 NORMAN Association; 2021 MassBank Consortium
Responsible: Dr. Tobias Schulze